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Polyunsaturated fatty acids in the pathogenesis and treatment of
multiple sclerosis
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Epidemiological, biochemical, animal model and clinical trial data described in this overview strongly suggest that polyunsaturated fatty acids,
particularly n-6 fatty acids, have a role in the pathogenesis and treatment of multiple sclerosis (MS). Data presented provides further evidence
for a disturbance in n-6 fatty acid metabolism in MS. Disturbance of n-6 fatty acid metabolism and dysregulation of cytokines are shown to
be linked and a “proof of concept clinical trial” further supports such a hypothesis. In a randomised double-blind, placebo controlled trial of a
high dose and low dose selected GLA (18 : 3n-6)-rich oil and placebo control, the high dose had a marked clinical effect in relapsing-remitting
MS, significantly decreasing the relapse rate and the progression of disease. Laboratory findings paralleled clinical changes in the placebo
group in that production of mononuclear cell pro-inflammatory cytokines (TNF-a, IL-1b) was increased and anti-inflammatory TGF-b markedly
decreased with loss of membrane n-6 fatty acids linoleic (18 : 2n-6) and arachidonic acids (20 : 4n-6). In contrast there were no such changes in the
high dose group. The improvement in disability (Expanded Disability Status Scale) in the high dose suggests there maybe a beneficial effect on
neuronal lipids and neural function in MS. Thus disturbed n-6 fatty acid metabolism in MS gives rise to loss of membrane long chain n-6 fatty
acids and loss of the anti-inflammatory regulatory cytokine TGF-b, particularly during the relapse phase, as well as loss of these important neural
fatty acids for CNS structure and function and consequent long term neurological deficit in MS.
Multiple sclerosis: Linoleic acid: Gamma-linolenic acid: Arachidonic acid: Clinical trials: Cytokines
Background to multiple sclerosis and its pathogenesis
Multiple sclerosis (MS) is a CNS-specific demyelinating dis-
ease, and is the most common neurological disorder that
occurs in young adults1,2. The majority of patients with MS
have the relapsing-remitting form of the disease, characterised
by attacks (relapses) interspersed with periods of recovery
(remission). The disease is most prevalent (30–100 þ cases
per 100 000 people) in Western Europe, Southern Canada,
Northern United States, Southern Australia and New Zealand
and of low frequency (0–19 per 100,000) in Asia, Central
America, Africa and Greenland (See Fig. 1). Between 2 and
3 million people Worldwide are thought to live with MS.
Although the aetiology of MS remains unknown there is
strong evidence for the presence of autoimmune mechanisms
in the disease pathogenesis3,4. Studies have shown that
MS patients have a much higher number of neuroantigen
e.g. myelin basic protein (MBP) and myelin oligodendrocyte
glycoprotein (MOG) autoreactive T-cells, which are in an
increased state of activation compared with healthy controls,
and which increase during exacerbation4 – 13.
Cytokines from activated T cells and macrophages have
been strongly implicated in the pathogenesis of MS14. For
example, the up-regulation of adhesion molecules on endo-
thelial cells and the subsequent infiltration of activated T
cells into the CNS are immunopathogenic events controlled
by pro-inflammatory cytokines such as tumour necrosis
factor-a (TNF-a), interleukin-1b (IL-1b) and interferon-g
(IFN-g)15. Furthermore studies have shown that these cyto-
kines exert direct myelinotoxic properties16,17 and prolong
the disease process in experimental autoimmune encephalo-
myelitis (EAE), an animal model of MS18,19,20. TNF-a,
IL-1b and IFN-g have all been shown to be present in
CNS active lesions in MS and elevated amounts of these
cytokines are secreted from MS peripheral blood mono-
nuclear cells (PBMC)21 – 25. Many studies, including our
own, have also shown that an increase in these inflammatory
cytokines coincides with the relapse phase of the dis-
ease25 – 33. Furthermore some studies have shown that
transforming growth factor-beta1 (TGF-b1), a potent anti-
inflammatory and immunosuppressive cytokine, is reduced
during the relapse phase and increases as the patient
enters remission25,34,35. In addition we have demonstrated
that the balance between biologically active TGF-b1 and
the pro-inflammatory TNF-a, IL-1b and IFN-g is dysregu-
lated during MS relapse-remission25. The actual processes
of axonal damage e.g. chronic inflammation, demyelination
and astrogliosis in MS is complex but white matter inflam-
mation and demyelination are considered to determine dis-
ease severity, whilst recent studies suggest that axonal
damage in MS begins in the early stages of the disease
and contributes to disability36,37. Furthermore some have
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considered metabolic disturbances in some MS patients to
be behind primary oligodendrocyte damage with secondary
autoimmune-demyelination38,39.
Nutritional epidemiology of multiple sclerosis
Over half a century ago Roy Swank40 found a positive
relationship between fat intake as well as annual milk pro-
duction and MS in Scandinavian countries. Furthermore
studies by Alter et al.41 implicated animal fat rich in satu-
rated fatty acids as a causal factor in MS and Wolfgram42
in an analysis of World Health Organisation (WHO) annual
mortality statistics found a similar geographical distribution
between MS coronary heart disease and cancer of the
colon. In the multivariate analysis (inclusive of socioeco-
nomic and medical services) of 20 countries Arganoff and
Goldberg43 not only implicated meat and dairy fats in posi-
tive correlations with MS, as noted previously, but also veg-
etable, seed, nut and fish, foods rich in both the n-6 and n-3
polyunsaturated fatty acids, in negative correlations with MS.
Several other studies also confirmed strong MS associations
with dairy and other animal fats44 – 46. Similar observations
have also been made more recently by Esparsa et al.47 in a
large study (36 countries) assessing the impact of diet on
MS mortality. They found that the higher the saturated
fatty acid intake the higher the MS mortality and the higher
the polyunsaturated to saturated fatty acid ratio the lower
the MS mortality. However the large single country study,
the Nurses’ Health Study in the USA failed to show any
relationship between MS and fat intake in women48. Thus
the majority of epidemiological studies indicate that foods
rich in saturated fatty acids are detrimentally associated
with MS, whilst polyunsaturated fatty acid rich foods are ben-
eficially associated with MS.
Biochemical and metabolic studies of fatty acids in
multiple sclerosis
There is much evidence that the n-6 fatty acids particularly
linoleic (18 : 2n-6) and arachidonic acids (20 : 4n-6) are
reduced in the plasma, platelets, erythrocytes, leucocytes and
cerebrospinal fluid with changes in the unsaturated fatty acid
composition of brain white matter in MS patients, much of
this early work being undertaken at the National Hospital,
Queen Square in London49 – 60. But there are also inconsistent
reports61 – 64and Love et al.65 observed that reduced linoleic
acid was not specific to MS and occurred in patients with
acute non-neurological illness. However many of these differ-
ences between studies are perhaps not surprising given cul-
tural and ethnic differences, dietary variability (particularly
when someone is ill), possible desaturase gene polymorphism,
disease variability, serum verses cellular fatty acids and meth-
odological differences for example total lipid fatty acids
verses phospholipids fatty acid analysis.
Previously we proposed nervonic acid as a marker of CNS
myelin damage in MS66 and found that MS patients consum-
ing a diet rich in polyunsaturated fatty acids particularly lino-
leic acid had an inverse relationship between erythrocyte
membrane linoleic acid and nervonic acid (24 : 1)67. A similar
finding was described by Homa et al.68, showing a decrease in
erythrocyte lignoceric acid (24 : 0) in sunflower oil (rich in
linoleic acid) supplemented MS patients. In an open, uncon-
trolled 2 year fish oil intervention study by Nordvik et al.69
in MS, they observed significant reductions in plasma total
phospholipid nervonic and lignoceric acids with time and
clinical improvement. Taken together the above indicate that
nervonic and lignoceric acids could be useful pathogenic bio-
markers of myelin damage and/or biomarkers for monitoring
fatty acid treatments. We also found that the atypical erythro-
cyte electrophoretic response of MS patients was positively
correlated with membrane linoleic acid and could be corrected
by a diet rich in polyunsaturated fatty acids particularly lino-
leic acid67. This is in agreement with Field and Joyce71 who
found an increase in erythrocyte electrophoretic response in
MS patients supplemented with evening primrose oil (EPO).
However, Field et al.71, Field and Joyce70 interpreted their
electrophoretic results, without an analysis of membrane
fatty acids, as an effect of the gamma-linolenic (GLA,
18 : 3n-6) component of the oil. EPO contains about 70 % lino-
leic acid and 8–10 % GLA, therefore it is more likely that the
effect observed by Field et al was due to the linoleic acid com-
ponent of the oil rather than the GLA.
We have also investigated the metabolic relationships
between the n-6 fatty acids in both healthy controls and MS
PBMC total phospholipids (Figs. 2, 3 and 4). Both controls
and MS patients (remission phase) demonstrate a positive cor-
relation between linoleic acid (18 : 2n-6) and arachidonic acid
(20 : 4n-6) as expected, although these n-6 fatty acids were
low in a proportion of the MS patients studied (Fig. 2). More-
over, the relationship between linoleic acid (18 : 2n-6) and
dihomo-g-linolenic acid (DGLA), and also between DGLA
(20 : 3n-6) and arachidonic acid (20 : 4n-6) is clearly disturbed
in MS compared with healthy controls (Figs. 3 and 4). This
may indicate a problem with D6 and D5 desaturation and /
or a greater requirement for these n-6 fatty acids in many
of the MS patients studied, about 20–30 percent of the
patients showed lower than normal PBMC phospholipid
DGLA and arachidonic acid. In agreement with our findings
Homa et al.55 has also reported a similar disturbance in the
relationship between linoleic acid and arachidonic acid in MS
erythrocyte membrane lipids compared to healthy controls.
Fig. 1. Geographical distribution of multiple sclerosis (from Adams C (1989)
colour atlas of multiple sclerosis and other myelin disorders, wolfe medical
publications ltd, with permission).
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Furthermore when we compared MS and healthy control
PBMC total phospholipid 20 : 2n-6 we found a significant 2
fold higher 20 : 2n-6 in MS patients in remission compared
to healthy controls and a significant 4 fold higher 20 : 2n-6
in the relapse phase of the disease. It appears that in MS
there is a very active elongation of 18 : 2n-6 to 20 : 2n-6 in
PBMCs and that this is even higher in the relapse phase
(accounting for the low 18 : 2n-6) indicating a disturbance in
the normal metabolism or a higher requirement for DGLA
and arachidonic acid (20 : 2n-6 maybe further D8 desaturated
to DGLA?) by these n-6 fatty acid (20 : 4n-6) rich cells72, or
both. This may also be reflective of the demand of cells and
myelin in the brain which are also n-6 fatty acid-rich
(20 : 4n-6 and 22 : 4n-6), significantly Stanley Rapoport of
the NIH has shown that the human brain requires 4 times
the amount of arachidonic acid (20 : 4n-6) than docosahexae-
noic acid (22 : 6n-3) on a daily bases (ISSFAL 2006). In
relation to 20 : 2n-6, although not discussed by the authors,
the Nordvik et al.69 study demonstrated a reduction with
time of 20 : 2n-6 running parallel with clinical improvement,
a similar finding to the nervonic and lignoceric acids men-
tioned earlier. Therefore 20 : 2n-6 may also be a useful
marker of disease progression and/or monitoring fatty acid
treatments in MS.
Fatty acids and animal models of multiple sclerosis
Experimental autoimmune encephalomyelitis (EAE) is an
experimentally induced CD4þT cell mediated autoimmune-
inflammatory and deyelinating disease in rodents often used
as an animal model of MS. Studies in guinea pig and rat
EAE treated with linoleic acid alone or a high linoleic and
low g-linolenic (GLA) acid rich oil (ratio 7 : 1) respectively,
have shown partial suppression of the incidence and severity
of EAE73,74. In a series of experiments we demonstrated
important disease modifying effects of linoleic acid-rich oil
(containing no GLA) and GLA-rich oil on clinical and histo-
pathological manifestations of EAE. Depending on dose GLA
was completely protective in EAE, whereas linoleic acid had
a dose dependent action on the clinical severity of EAE,
although not abolishing it75,76. Natural recovery in EAE is
mediated by expansion of suppressor lymphoid cells77 some
of which have been characterised as TGF-b producing
CD4þT cells by Karpus and Swanborg78. Furthermore admin-
istration of TGF-b protects in acute and relapsing EAE79,80
and prostaglandin inhibitors such as indomethacin augment
EAE81. In-addition during the natural recovery phase from
EAE TGF-b secreting T cells can inhibit EAE effector cells
and TGF-b is expressed in the CNS78,82,83. Consistent with
these findings the protective effect of GLA-rich oil in EAE is
linked to increased T cell TGF-b transcription and increased
production of PGE2
76.
Fig. 2. Relationship between linoleic acid (18 : 2n-6) and arachidonic acid
(20 : 4n-6) in peripheral blood mononuclear cell total phospholipids of healthy
controls and multiple sclerosis.
Fig. 3. Relationship between linoleic acid (18 : 2n-6) and dihomo-g-linolenic
acid (20 : 3n-6) in peripheral blood mononuclear cell total phospholipids of
healthy controls and multiple sclerosis.
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Clinical trials and intervention studies in multiple sclerosis
with fatty acids
Clinical trials to test the efficacy of linoleic acid-rich sun-
flower oil in MS patients by Miller et al.84 and Bates et al.85
over 2 years showed a reduction in the relapse rate and sever-
ity of the disease relapse, but Paty et al.86 found no such
effect. Nevertheless, Dworkin et al.87 in a statistical revalua-
tion of the combined data of all three trials revealed signifi-
cantly reduced relapse rate and severity, and in mildly
affected a decrease in the long term progression of the disease.
The Millar et al.84 study based in two centres London and Bel-
fast is particularly interesting as they observed that “the sever-
ity of the relapses, differed markedly between the treated and
the control groups at both centres” relapses being twice as
severe in the control group. Compared with current b-inter-
feron treatment of MS the efficacy of linoleic acid-rich sun-
flower oil in the Miller et al study is quite remarkable. Fish
oil rich in long chain n-3 fatty acids has also been studied
in MS88, no significant differences between fish oil treated
and untreated MS patients was observed, there was, however,
a trend for less deterioration in the fish oil treated group. In a 2
year open intervention study MS patients given fish oil and
advised to lower their saturated fat intake had significant
reductions in the relapse rate and disability progression as
measured by the Expanded Disability Status Scale (EDSS)69
which quantifies disability in MS in eight functional systems
(pyramidal, cerebellar, brainstem, sensory, bowel and bladder,
visual, cerebral, other). It also appears based on open studies
by us and by Roy Swank that long term low saturated fat
diets containing both n-6 and n-3 fatty acids improve the
course of the disease89 – 93.
Based on our MS fatty acid metabolic data and experimen-
tal animal model work, described above, we undertook a ran-
domised double-blind placebo controlled trial to determine the
effects of supplementation with a selected GLA (18 : 3n-6)-
rich borage oil. This oil, BGC20-884 was high in sn-2 GLA,
low in monoenes and contained only natural levels of vitamin
E. This study evaluated two doses of BGC20-884 (low dose -
5 gram and high dose - 14 gram per day) and a placebo control
(polyethylene glycol 400) on the clinical course and PBMC
cytokine and membrane fatty acid profiles of 36 patients
with active MS over 18 months94. Patients were diagnosed
and assessed using international criteria for MS. Relapse
rate and EDSS (Expanded Disability Status Scale) were
assessed every three months and blood taken and PBMCs iso-
lated for cytokine studies and membrane fatty acids. High
dose BGC20-884 treatment markedly and significantly
reduced the relapse rate (Fig. 5) and disability progression
as measured by EDSS (Fig. 6) compared with the placebo con-
trol and low dose BGC20-884 treatment. In patients where we
had follow up samples available PBMC cytokine changes
were found to run parallel with the clinical findings e.g. the
placebo control group showed significant decreases in the
TGF-b/TNF-a and TGF-b/IL-1b ratios and associated loss of
n-6 fatty acids particularly linoleic (18 : 2n-6) and arachidonic
acid (20 : 4n-6) over time. Consistent with our findings
Navarro and Segura59 also found significant loss of
linoleic and arachidonic acids over time in MS erythrocyte
phospholipids. In contrast high dose BGC20-884 treatment
showed no changes in TGF-b/TNF-a and TGF-b/IL-1b
ratios and no changes in membrane n-6 fatty acids compared
with the placebo group. We also found positive correlations
between PBMC phospholipid arachidonic acid composition
and TGF-b1 production (r ¼ 0·26, P , 0·02, n ¼ 73)
and DGLA and TGF-b1 production (r ¼ 0·36, P , 0·001,
n ¼ 74) ex vivo when all samples were included in the
analysis. The EDSS improvement in the high dose group
Fig. 4. Relationship between dihomo-g-linolenic acid (20 : 3n-6) and arachido-
nic acid (20 : 4n-6) in peripheral blood mononuclear cell total phospholipids of
healthy controls and multiple sclerosis.
Fig. 5. Mean annualised relapse rate per patient for multiple sclerosis
patients receiving high (n ¼ 11) and low dose (n ¼ 7) GLA-rich oil or placebo
control (n ¼ 10) over 18 months.
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also suggests there maybe a beneficial effect on neuronal
lipids and neural function in MS. The study thus further sup-
ports our hypothesis of dysregulation of fatty acid metabolism
and cytokines in MS25,76.
To summarise and extend this section on clinical trials there
is evidence to show a beneficial effect of n-6 and possibly n-3
fatty acids in MS. The mechanisms by which the n-3 or the
n-6 fatty acids influence the immune-inflammatory response
in MS are however likely to be different72. Both the n-6 (ara-
chidonic acid) and n-3 (docosahexaenoic acid) fatty acids are
important for neural structure and function95 – 101 and this
aspect may explain studies where improvements in EDSS
have also been reported. Furthermore requirements for essen-
tial polyunsaturated fatty acids increase as a function of the
amount of saturated fat in the diet102 and we have recently
found significant positive correlations between dietary total
saturated and total monounsaturated fatty acids and delta-6
and delta-5 desaturase gene expression in human PBMC103.
The level of dietary saturated and monounsaturated fatty
acids should not therefore be ignored and may be important
factors in some of the trials discussed above and relate to
the MS epidemiological correlations, mentioned earlier in
this overview, in relation to an increased requirement for poly-
unsaturated fatty acids in MS.
Conclusions and perspectives
Taken overall the epidemiological, biochemical, experimental
animal model and clinical trial data described in this overview
show that polyunsaturated fatty acids, particularly the n-6 fatty
acids, do have a role in the pathogenesis and treatment of mul-
tiple sclerosis. We have demonstrated dysregulation of n-6
fatty acid metabolism and cytokines in MS and have been
able to show in a small “proof of concept” clinical trial a
marked therapeutic benefit. Thus we suggest that dysregula-
tion of n-6 fatty acid metabolism and cytokines is one mech-
anism that is important in disease progression, which is
modifiable by specific supplementation. Thus metabolic dis-
turbance of the production of the long chain n-6 fatty acids
DGLA and AA affects the physiological integrity of
immune cells, in that they have a limited ability to produce
TGF-b, under relapse conditions, which is important for the
regulation of pro-inflammatory cytokine production e.g.
TNF-a, IL-1b, IFN-g as well as other cellular biological
functions. It is also known that TGF-b and fatty acids such
as arachidonic acid are important in the growth and differen-
tiation of oligodendrocytes and in myelination104 – 108 which
would therefore be of importance in the stimulation, growth
and recovery of these cells in MS. These findings provide a
link between, dietary, metabolic, immunological and neuro-
biological aspects of MS and therefore for the first time we
can begin to make sense of the wealth of apparently uncon-
nected aspects of MS, particularly in relation to dietary fats.
More basic research is still required such as characterisation
of possible desaturase gene polymorphisms, lymphocyte desa-
turase gene expression and analysis of specific lymphocyte
phospholipid classes and their fatty acid composition in
relation to cytokine and chemokine gene expression and pro-
duction. This should be undertaken in well defined MS patient
groups e.g. active MS and primary and secondary chronic pro-
gressive forms of the disease and over an extended period of
time. Furthermore large well controlled clinical trials with
different doses of well characterised and safe fatty acid formu-
lations as well as manipulation of dietary saturated fatty acids
could be undertaken. Clinical trials should include MRI, MR
spectroscopy and analysis of lesion burden and cortical gray
matter density in order to investigate any possible effects of
polyunsaturated fatty acids on myelination, neuronal, dentritic,
glial and neurite packing densities. In addition biochemical
monitoring of peripheral blood cell membrane phospholipid
fatty acids, particularly lymphocytes, should be undertaken
as well as immunological studies such as T-cell and macro-
phage pro- and anti-inflammatory cytokine gene expression
and production, T regulatory cells and anti-myelin antibodies.
In this way a more complete picture will emerge of the clinical
and therapeutic significance and the metabolic, immunological
and neurological bases to the role of polyunsaturated fatty
acids in the pathogenesis and treatment of MS.
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